Rasanco

Rasanco is a pre-clinical stage biotechnology company dedicated to developing next-generation small molecule inhibitors targeting the RAS oncogene family. The company focuses on addressing the limitations of first-generation KRAS inhibitors by targeting a broader range of mutations, including KRAS G12D, G12V, and G13D, which are prevalent in pancreatic, colorectal, and lung cancers. By utilizing advanced structure-based drug design and medicinal chemistry, Rasanco aims to create highly selective and potent therapies for patients with RAS-driven malignancies that currently have limited treatment options. The company operates primarily in the oncology space, seeking to transform the treatment landscape for some of the most difficult-to-treat solid tumors.